Navigation Links
New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen
Date:11/13/2007

Fast-dissolve method uses the latest advancement in aspirin delivery

technology.

CLEVELAND, Nov. 13 /PRNewswire/ -- Improvita Health Products, Inc. has rolled out Fasprin(R), a patented, 81 milligram aspirin tablet that dissolves rapidly in the mouth instead of in the stomach, offering an effective, simplified solution for the millions of Americans who maintain a daily aspirin routine and worry about gastrointestinal bleeding or swallowing pills.

A daily low-dose aspirin therapy is commonly prescribed to adults to prevent heart attack and stroke and help improve blood flow to the heart. Small daily doses of aspirin have proven to be effective in reducing the chances of mini-strokes (in which clogged blood vessels prevent sufficient oxygen from reaching the brain). Aspirin is also used to reduce the risk of heart attack in people with clogged coronary arteries, and in those who've already had an attack.

With its great-tasting "citrus burst" flavor, Fasprin is ideal for patients on a daily heart health aspirin regimen and is sugar free for diabetics.

Fasprin's patented, no-swallow aspirin delivery method reduces irritation to the gastrointestinal tract by quickly dissolving in the mouth, which allows the aspirin to enter the blood stream in just three to five minutes, or up to ten times faster than conventional aspirin that typically is absorbed through the stomach.

Tom Klamet, president of Improvita Health Products, Inc., noted that the low-dose aspirin tablet uses the latest technology for delivering the required dosage to the blood stream. "Fasprin was developed by a physician who saw the many benefits of an aspirin that could be administered quickly and effortlessly," he commented. "A daily aspirin regimen can fast become a chore, especially for older adults who have a hard time swallowing a full tablet. Fasprin's ability to dissolve on the tongue ensures 100 percent bioavailability, or the delivery of the entire aspirin into the blood stream."

Some studies have shown that enteric-coated aspirin delivers just 50 percent of the dosage before the remaining tablet is eliminated by the body.

The quick-dissolve absorption also makes Fasprin the delivery of choice at the onset of a heart attack or stroke, where doctors recommend immediately administering aspirin. By doing so, aspirin can reduce the risk of death by as much as 23 percent, according to published studies.

Fasprin comes in a 30-tablet package (a month's supply), and carries a suggested retail price of $5.99. Fasprin is available wherever aspirin is sold, including Walgreens, CVS, Rite Aid, Albertsons, Meijer and Wal-Mart. The product is also available through the company's website at http://www.Fasprin.com.

[Product photos and additional stories available at http://www.improvita.com/fasprin-news.]

Contact:

Steve Corcoran

Vice President

Hybrid Marketing

Phone: 216-774-9274

Cell: 440-655-6073

corc@hybridmar.com

Tom Klamet

President

Improvita Health Products, Inc.

Phone: (216) 573-1850

tklamet@improvita.com


'/>"/>
SOURCE Improvita Health Products, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: